Raymond James Financial
VRCA icon

Raymond James Financial’s Verrica Pharmaceuticals VRCA Stock Holding History

Raymond James Financial’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-840
Closed -$4.45K – 6743
2025
Q2 		$4.45K Buy
+840
New +$4.52K ﹤0.01% 6201

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Raymond James Financial's VRCA Position: Q3 2025 in Review

Raymond James Financial sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 840 shares — an estimated $4.45K sold.

Raymond James Financial first reported a position in VRCA in Q2 2025 and held it in 1 quarter. The position peaked at $4.45K in Q2 2025. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • Raymond James Financial reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 840 Verrica Pharmaceuticals shares in Q3 2025, an estimated $4.45K.
  • Raymond James Financial first reported a position in Verrica Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Verrica Pharmaceuticals position peaked at $4.45K in Q2 2025.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.